Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells

Brain Pathology

Volumn 22, Issue 2, 2012, Pages 159-174

  Avril, Tony ^a   Vauleon, Elodie ^a,b   Hamlat, Abderrahmane ^c   Saikali, Stéphan ^c   Etcheverry, Amandine ^b   Delmas, Caroline ^d   Diabira, Sylma ^c   Mosser, Jean ^b   Quillien, Véronique ^a,b  

^a CENTRE EUGÈNE MARQUIS   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

cancer stem cells; cell therapy; cytotoxic T cells; glioblastoma; NK cells

Indexed keywords

CETUXIMAB; LECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ARTICLE; CANCER IMMUNOTHERAPY; CYTOLYSIS; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NATURAL KILLER CELL; RECURRENT DISEASE; T LYMPHOCYTE;

BRAIN NEOPLASMS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; GLIOBLASTOMA; HUMANS; KILLER CELLS, NATURAL; NEOPLASTIC STEM CELLS; SPHEROIDS, CELLULAR; T-LYMPHOCYTE SUBSETS;

EID: 84855684581     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00515.x     Document Type: Article

References (75)

1. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, et al, (2010) HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16: 474-485.
2. Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B, (2010) Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res 16: 3399-3408.
3. Aulwurm S, Wischhusen J, Friese M, Borst J, Weller M, (2006) Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer 118: 1728-1735.
4. Avril T, Jarousseau AC, Watier H, Boucraut J, Le Bouteiller P, Bardos P, Thibault G, (1999) Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism. J Immunol 162: 5902-5909.
5. Avril T, Saikali S, Vauleon E, Jary A, Hamlat A, De Tayrac M, et al, (2010) Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol 225: 22-33.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al, (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
7. Barcia C Jr, Gomez A, Gallego-Sanchez JM, Perez-Valles A, Castro MG, Lowenstein PR, et al, (2009) Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am J Pathol 175: 786-798.
8. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, et al, (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68: 5706-5715.
9. Belda-Iniesta C, Carpeno JC, Saenz EC, Gutierrez M, Perona R, Baron MG, (2006) Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther 5: 912-914.
10. Biassoni R, (2008) Natural killer cell receptors. Adv Exp Med Biol 640: 35-52.
11. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC, (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235.
12. Blery M, Olcese L, Vivier E, (2000) Early signaling via inhibitory and activating NK receptors. Hum Immunol 61: 51-64.
13. Bonnet D, Dick JE, (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
14. Brown CE, Starr R, Martinez C, Aguilar B, D'Apuzzo M, Todorov I, et al, (2009) Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res 69: 8886-8893.
15. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al, (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
16. Carlsten M, Malmberg KJ, Ljunggren HG, (2009) Natural killer cell-mediated lysis of freshly isolated human tumor cells. Int J Cancer 124: 757-762.
17. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, et al, (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182: 3530-3539.
18. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al, (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344.
19. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, et al, (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14: 3098-3104.
20. De Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, van Gool S, Sabel M, (2006) Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 59: 988-999.
21. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, et al, (2010) Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 16: 800-813.
22. Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, et al, (2006) Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res 66: 5883-5891.
23. Ehtesham M, Black KL, Yu JS, (2004) Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11: 192-207.
24. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, et al, (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13: 1238-1241.
25. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al, (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021.
26. Gerber DE, Choy H, (2010) Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev 29: 171-180.
27. Ginzkey C, Eicker SO, Marget M, Krause J, Brecht S, Westphal M, et al, (2010) Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model. Cancer Immunol Immunother 59: 541-551.
28. Hadjipanayis CG, Van Meir EG, (2009) Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med 15: 519-530.
29. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sorensen M, Kosteljanetz M, et al, (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12: 508-516.
30. Holland EC, (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 97: 6242-6244.
31. Hong X, Miller C, Savant-Bhonsale S, Kalkanis SN, (2009) Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery 64: 1139-1146.
32. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, et al, (2006) Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 66: 8887-8896.
33. Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS, (2009) Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 6: 500-512.
34. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, et al, (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104: 170-177.
35. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA, (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193-206.
36. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T, (2004) Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24: 1861-1871.
37. Jordan CT, Guzman ML, Noble M, (2006) Cancer stem cells. N Engl J Med 355: 1253-1261.
38. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC, (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64: 9160-9166.
39. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, et al, (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27: 452-459.
40. Kruser TJ, Wheeler DL, (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316: 1083-1100.
41. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH, (1991) Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 146: 4421-4426.
42. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al, (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
43. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al, (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11: 5515-5525.
44. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al, (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67.
45. Martens T, Laabs Y, Gunther HS, Kemming D, Zhu Z, Witte L, et al, (2008) Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res 14: 5447-5458.
46. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ, (2009) CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 15: 5145-5153.
47. Miller J, Eisele G, Tabatabai G, Aulwurm S, von Kürthy G, Stitz L, et al, (2010) Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. J Neurosurg 113: 280-285.
48. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, et al, (2009) Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 20: 1596-1603.
49. Park DM, Rich JN, (2009) Biology of glioma cancer stem cells. Mol Cells 28: 7-12.
50. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, et al, (2006) Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 66: 10247-10252.
51. Reilly KM, Rubin JB, Gilbertson RJ, Garbow JR, Roussel MF, Gutmann DH, (2008) Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop. Cancer Res 68: 5508-5511.
52. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
53. Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M, (2007) Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res 67: 3540-3544.
54. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, et al, (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81: 139-148.
55. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB, (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
56. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al, (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
57. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al, (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide vs. radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
58. Ueda R, Ohkusu-Tsukada K, Fusaki N, Soeda A, Kawase T, Kawakami Y, Toda M, (2010) Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer 126: 919-929.
59. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, et al, (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961.
60. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, et al, (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187: 2065-2072.
61. Walzer T, Jaeger S, Chaix J, Vivier E, (2007) Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol 19: 365-372.
62. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al, (2010) Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 16: 461-473.
63. Wheeler CJ, (2010) Dendritic cell vaccines to combat glioblastoma. Expert Rev Neurother 10: 483-486.
64. Wicha MS, (2006) Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 12: 5606-5607.
65. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, et al, (2002) Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62: 2592-2599.
66. Wu A, Wiesner S, Xiao J, Ericson K, Chen W, Hall WA, et al, (2007) Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J Neurooncol 83: 121-131.
67. Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK, et al, (2006) Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 76: 23-30.
68. Xie Z, Chin LS, (2008) Molecular and cell biology of brain tumor stem cells: lessons from neural progenitor/stem cells. Neurosurg Focus 24: E25.
69. Yamanaka R, (2009) Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 32: 265-273.
70. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al, (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89: 1172-1179.
71. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al, (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11: 4160-4167.
72. Yan X, Su Z, Zhang J, Wu Z, Ye S, Lu X, et al, (2010) Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells. Cell Immunol 263: 172-175.
73. Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou LF, (2009) B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol 11: 757-766.
74. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ, (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973-4979.
75. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, et al, (2004) Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23: 9392-9400.